Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNV3837 in Clostridium Difficile Infection
NCT03988855Phase 2Unknown
- Sponsor
- Deinove
- Start
- Aug 2019
- Primary completion
- Dec 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of DNV3837 in Clostridium difficile infection (CDI) (2 arms), sponsored by Deinove. Primary endpoints: Time to resolution of diarrhea at Day 12, Treatment Success at Test of Cure at Day 12 and 4 more. Status: unknown.
02
Drugs
DNV3837
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT03988855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988855.